Form 4: Coya Therapeutics CEO Acquires Stock Options
SEC Form 4 Filing
Coya Therapeutics CEO, Arun Swaminathan, was granted 240,964 stock options on January 9, 2025, which vest over 36 months.
Summary
- Arun Swaminathan, the Chief Executive Officer of Coya Therapeutics, Inc., was granted 240,964 stock options on January 9, 2025.
- The options have an exercise price of $6.07 per share.
- The options will vest in monthly installments over 36 months, starting on February 9, 2025, contingent upon continued service.
- The options expire on January 9, 2035.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.
Positives
- The granting of stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Risks
- The value of the options is dependent on the future performance of Coya Therapeutics' stock price.
- If the CEO leaves the company before the options fully vest, he may forfeit some or all of the options.
Future Outlook
The CEO's stock options will vest over the next 36 months, contingent on continued service.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard practice for incentivizing executives in publicly traded companies, particularly in the biotech sector.
- The vesting schedule of 36 months is typical for such grants, ensuring long-term commitment from the executive.
- The exercise price of $6.07 is a specific value for this grant and would need to be compared to other similar grants to determine if it is in line with industry standards.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the CEO to increase the company's value.
- Employees may see this as a sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 01/09/2025 | Date of the stock option grant. |
| 02/09/2025 | Start date for monthly vesting of the stock options. |
| 01/09/2035 | Expiration date of the stock options. |
| 01/13/2025 | Date of the filing of the SEC Form 4. |
Keywords
stock options, executive compensation, insider trading, Coya Therapeutics, Arun Swaminathan, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.